Abstract 2166: Analysis of ctDNA next generation sequencing (NGS) for predicting response to amivantamab and lazertinib among patients with EGFR-mutant NSCLC after progression on osimertinib and platinum-based chemotherapy (CHRYSALIS-2 Cohort A)
Year: 2023
Type: conference-abstract
Source: Cancer Research
Authors: Rachel E. Sanborn, Saiama N. Waqar, Byoung Chul Cho, Benjamin Besse, Koichi Goto, Yongsheng Wang, Se-Hoon Lee, Melina E. Marmarelis, Yuichiro Ohe, Dong-Wan Kim, Antonio Calles, Joel Neal, Christina S. Baik, Pasi A. Janne, Joshua C. Curtin, Bharvin Patel, Mike Gormley, S. Martin Shreeve, Joshua M. Bauml, Roland E. Knoblauch, James Chih-Hsin Yang
Institutions: Providence Portland Medical Center, Washington University in St. Louis, Yonsei University, Yonsei University Health System, Yonsei Cancer Hospital, Institut Gustave Roussy, National Cancer Center Hospital East, Sichuan University, West China Hospital of Sichuan University, Samsung Medical Center, Sungkyunkwan University, Hospital of the University of Pennsylvania, University of Pennsylvania, National Cancer Centre Japan, Seoul National University, Hospital General Universitario Gregorio Marañón, Stanford Medicine, University of Washington, Fred Hutch Cancer Center, Dana-Farber Cancer Institute, Janssen Research & Development (United States), National Taiwan University
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4362592515